This brand name is authorized in Japan
The drug TENELIA contains one active pharmaceutical ingredient (API):
|
1
Teneligliptin
UNII 15S4OCS6SS - TENELIGLIPTIN HYDROBROMIDE HYDRATE
|
|
Teneligliptin is a potent, selective, and long-lasting DPP-4 inhibitor. It acts as a competitive reversible inhibitor of DPP-4 and decreases the degradation of incretins, especially GLP-1, thereby improving hyperglycemia by stimulating insulin secretion and suppressing glucagon secretion in a glucose-dependent manner (no or negligible risk of hypoglycemia). |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A10BH08 | A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: JP | 医薬品医療機器総合機構 | Identifier(s): 3969015F1029, 3969015F2025, 3969015F3021, 3969015F4028 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
